

Common variants at the PCOL2 and Sp1 binding sites of the COL1A1 gene and their interactive effect influence bone mineral density in Caucasians

P-Y Liu, Y Lu, J-R Long, F-H Xu, H Shen, R R Recker, H-W Deng

J Med Genet 2004;41:752–757. doi: 10.1136/jmg.2004.019851

See end of article for authors' affiliations

Correspondence to:
Dr H-W Deng,
Osteoporosis Research
Center, Creighton
University Medical Center,
601 N. 30th St., Suite
6787, Omaha, NE 68131,
USA; deng@creighton.edu

Revised version received
22 March 2004
Accepted for publication
17 April 2004

Osteoporosis is a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.¹ The collagen type I alpha 1 (*COL1A1*) gene is a prominent candidate gene for osteoporosis.² It is located at chromosome 17q21.31–q22 and encodes the alpha 1 chain of type I collagen, the most abundant protein of the bone matrix. Mutations in the *COL1A1* gene can cause osteogenesis imperfecta, a disease characterised by moderate to severe bone fragility.³ The similar bone brittleness observed in osteogenesis imperfecta and in osteoporosis makes it interesting to speculate that osteoporosis may also be caused by mutations of the *COL1A1* gene. Functional studies showed that the Sp1 polymorphism in intron 1 alters binding of Sp1 to its recognition site and is associated with disturbances in *COL1A1* transcription, collagen protein production, and the biomechanical properties of bone.⁴ These polymorphisms in the *COL1A1* gene have been frequently studied as genetic markers for osteoporosis association studies.^{2 5–13}

In genetic association studies, many surrogate phenotypes are usually recorded for complex diseases. For instance, a wide variety of skeletal phenotypes are used in genetic studies of osteoporosis, including bone mineral density (BMD), quantitative ultrasound measurements, and bone turnover.¹⁴ A common approach dealing with multiple phenotypes is to use multi-fold univariate tests, that is, testing association for each phenotype at one time. This may result in a multiple testing problem. For example, the type I error of the whole experiment may dramatically exceed the nominal level. Furthermore, univariate analysis may lose rich information on the correlation structure between

Background: Osteoporosis, mainly characterised by low bone mineral density (BMD), is a serious public health problem. The collagen type I alpha 1 (*COL1A1*) gene is a prominent candidate gene for osteoporosis. Here, we examined whether genetic variants at the *COL1A1* gene can influence BMD variation.

Methods: BMD was measured at nine skeletal sites in 313 Caucasian males and 308 Caucasian females. We screened four single nucleotide polymorphisms (SNPs) at the *COL1A1* gene: PCOL2 (-1997 G/T) in the promoter, Sp1 (1546 G/T) in the intron 1, Gly19Cys (3911 G/A) in exon 8, and Ala897Thr (13 773 G/A) in exon 45. Univariate and multivariate association approaches were used in the analyses.

Results: In multivariate analyses, we found a strong association between the PCOL2 SNP and BMD ($p=0.007$ to 0.024) and a suggestive association between the Sp1 SNP and BMD ($p=0.023$ to 0.048) in elderly Caucasian females. Interestingly, the interaction of these two SNPs was highly significantly associated with BMD variation ($p=0.001$ to 0.003). The haplotype GG at the two SNPs had, on average, 2.7% higher BMD than non-carriers ($p=0.006$ to 0.026).

Conclusions: Our data suggested that the common genetic variants at the PCOL2 and Sp1 sites, and importantly, their interactive effects, may contribute to BMD variation in elderly Caucasian females. Further studies are necessary to delineate the mechanisms underlying the effects of these common variants on BMD variation and to test their clinical relevance for general populations. In addition, our study highlighted the importance of multivariate analyses when multiple correlated phenotypes are under study.

phenotypes. Multivariate association analysis may overcome some of these limitations of univariate analysis.

In the present study, we aim to examine whether genetic variants at the *COL1A1* gene can influence BMD variation. BMD phenotypes were measured by dual energy X-ray absorptiometry (DXA) at nine skeletal sites in a random sample of Caucasian origin. We screened four single nucleotide polymorphisms (SNPs) at the *COL1A1* gene: PCOL2 (-1997 G/T) in the promoter, Sp1 (1546 G/T) in intron 1, Gly19Cys (3911 G/A) in exon 8, and Ala897Thr (13 773 G/A) in exon 45. Association of these BMD phenotypes with the common SNPs and their haplotypes was analysed, comparatively, by two different approaches: univariate and multivariate association analyses.

METHODS

Subjects and measurement

A cohort of 313 males and 308 females were selected from 405 nuclear families that were recruited for genetic studies aimed at searching for genes underlying osteoporosis. The selected subjects for association analyses were unrelated. The study was approved by the Creighton University institutional review board. All subjects were Caucasians of European origin. Only healthy people were included with the exclusion criteria detailed earlier by ourselves.¹⁵ Briefly, patients with chronic diseases and conditions which may potentially affect

Abbreviations: BMD, bone mineral density; DXA, dual energy X-ray absorptiometry; FS, factor scores; MANOVA, multivariate ANOVA; PCA, principal component analysis; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; TDT, transmission disequilibrium tests; UANOVA, univariate analysis of variance

bone mass were excluded from the study. These diseases/conditions include chronic disorders involving vital organs (heart, lung, liver, kidney, and brain), serious metabolic diseases (diabetes, hypo- and hyperparathyroidism, and hyperthyroidism, etc), other skeletal diseases (Paget disease, osteogenesis imperfecta, and rheumatoid arthritis, etc), chronic use of drugs affecting bone metabolism (corticosteroid therapy and anti-convulsant drugs), and malnutrition conditions (chronic diarrhoea and chronic ulcerative colitis, etc). All the study subjects signed informed consent documents before entering the study. For each study subject, we obtained information on age, sex, medical history, family history, female history, physical activity, alcohol use, diet habits, and smoking history.

BMDs (g/cm^2) of the lumbar spine; femoral neck, trochanter, and intertrochanter regions at the hip; ultradistal, mid-distal, and one-third regions at the wrist; and total body were measured by a Hologic 2000+ or a 4500 DXA scanner (Hologic, Bedford, MA, USA). For the spine, the quantitative phenotype was combined BMD of L1–L4. For the hip, the quantitative phenotype was combined BMD at femoral neck, trochanter, and intertrochanter regions. Both of the machines were calibrated daily, and the coefficient of variability values of the DXA measurements at the spine, hip, femoral neck, trochanter, intertrochanter, ultradistal, mid-distal, one-third, and total body regions were 0.8, 1.0, 1.87, 1.22, 1.25, 2.55, 1.06, 1.13, and 1.13% on the Hologic 2000+, and 0.9, 1.4, 1.98, 1.18, 1.72, 2.28, 1.32, 1.32, and 0.98% on the Hologic 4500, respectively. In total 92% of the subjects were measured on the Hologic 4500 scanner. Data obtained from different machines were transformed to a compatible measurement,¹⁶ which has been shown to be highly reliable and accurate.¹⁷ Members of the same nuclear family were measured on the same scanner. At the same visit as the BMD scan, weight was measured using a calibrated balance beam scale; height was measured using a calibrated stadiometer (table 1).

SNPs genotyping

After searching the dbSNP database (www.ncbi.nlm.nih.gov/SNP/) and reviewing previously published studies, four SNPs were selected in the *COL1A1* gene in the study (table 2). The selected SNPs for the study were based on a comprehensive consideration of: (i) functional relevance and importance, (ii) position in or around the gene, and (iii) their use in previous genetic epidemiology studies.^{2 18 19}

Genomic DNA was extracted from whole blood using a commercial isolation kit (Gentra Systems, Minneapolis, MN, USA) following the procedure detailed in the kit. The genotyping procedure for all SNPs was similar, involving polymerase chain reaction (PCR) and Invader assay (Third

Wave Technology, Madison, WI, USA). PCR was performed in 10 μl reaction volume with 35 ng genomic DNA, 0.2 mM each of dCTP, dATP, dGTP, and dTTP, 1 \times PCR buffer and 1.5 mM MgCl_2 , 0.4 μM each of the primers, and 0.35 U Taq polymerase (ABI, Applied Biosystems, Foster City, CA, USA). The sequences of the PCR primers for the four SNPs are presented in table 2. The following procedure was used on 9700 Thermal Cyclers: 95°C for 5 min, 30 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min, and then 72°C for 5 min. After amplification, the product was diluted 1:20 in nuclease-free water. The Invader reaction was performed in a 7.5 μl reaction volume, with 3.75 μl diluted PCR product, 1.5 μl probe mix, 1.75 μl Cleavase FRET mix, and 0.5 μl Cleavase enzyme/ MgCl_2 solution (Third Wave Technology). The reaction mix was overlaid by 15 μl mineral oil and denatured at 95°C for 5 min, and then incubated at 63°C for 20 min on 9700 Thermal Cyclers. After incubation, the fluorescence intensity for both colours (FAM and Red dyes) was read out using Cytofluor 4000 (ABI). The data were then loaded to the software Invader Analyzer (Third Wave Technology), and the genotype for every sample was called according to the ratio of the fluorescence intensity of the two dyes. The PedCheck program (http://watson.hgen.pitt.edu/register/soft_doc.html) was used to verify Mendelian inheritance of the alleles within each family and the family relationships.²⁰

Statistical analyses

Univariate analysis

Association of the *COL1A1* gene with BMD can be tested by using univariate analysis of variance (UANOVA), with different genotypes as main effects and BMD of different subjects within each genotype as random effects. UANOVA analyses were performed for each of the nine BMD phenotypes separately. The test statistic for UANOVA is the F statistic, which measures the ratio of between-group variability to within-group variability. Significant results may indicate genotypic difference in BMD variation (that is, declaring an association of the *COL1A1* gene with BMD).

Multivariate analysis

Unlike UANOVA, multivariate ANOVA (MANOVA) can be used to test joint genotypic differences in multiple BMD phenotypes. Two commonly used test statistics for MANOVA were adopted in our analyses: Wilks' lambda and Roy's largest root. The former is an exact F statistic and the later is an upper bound F statistic.²¹ In the MANOVA analyses, partial correlation coefficients between different BMD phenotypes were estimated, and their significance was tested. The partial correlation measures the strength of relationship between two variables, controlling for the effects of other variables.

Principal component analysis (PCA)

BMD variation at various skeletal sites may share common genetic sources.^{22–25} The correlation analysis showed that BMD phenotypes are significantly correlated among different skeletal sites in our sample (table 3). Therefore, a stabilised multivariate analysis²⁶ based on linear scores of multiple phenotypes obtained from PCA was performed on our data as follows. First, PCA of the covariance matrix of the nine BMD phenotypes was conducted and factor scores (FS) for each individual were calculated. Then, UANOVA analyses were performed for the three principal FS separately (see Results). The aforementioned MANOVA analysis of these FS was also performed.

Each of the common SNPs and their haplotypes at the *COL1A1* gene were analysed separately. The haplotypes were reconstructed according to all subjects from the nuclear

Table 1 Basic characteristics of the study subjects in male and female groups

	Male (n=308)	Female (n=313)
Age (SD), years	62.46 (10.75)	61.91 (10.76)
Height (SD), cm	176.62 (6.74)	161.88 (6.31)
Weight (SD), kg	89.85 (14.80)	73.56 (15.48)
BMD, g/cm^2		
Lumbar spine (SD)	1.0708 (0.1732)	0.9940 (0.1787)
Total hip (SD)	1.0159 (0.1414)	0.8901 (0.1579)
Femoral neck (SD)	0.8094 (0.1285)	0.7431 (0.1298)
Trochanter (SD)	0.7894 (0.1263)	0.6738 (0.1332)
Intertrochanter (SD)	1.1908 (0.1693)	1.0548 (0.1921)
Ultradistal (SD)	0.4950 (0.0772)	0.4103 (0.0785)
Mid-distal (SD)	0.6764 (0.0718)	0.5734 (0.0877)
One-third (SD)	0.7958 (0.0704)	0.6550 (0.0934)
Total body (SD)	1.1830 (0.1079)	1.0819 (0.1228)

Values are mean (SD). The reported BMD are raw phenotype data.

Table 2 Information and the primer sequences for the studied SNPs in the *COL1A1* gene

SNP	dbSNP* or reference	Polymorphism†	Frequency‡	Location in genes	Primers (5'-3')
PCOL2	Garcia-Giralt <i>et al</i> ¹⁹	-1997 G/T	0.152	Promoter	F: GCACCTGCCTAGACCAC R: CCTAGTGCCAGCGACTGCA
Sp1¶	Grant <i>et al</i> ²	1546 G/T	0.187	Intron 1 (3543)	F: CCAATCAGCCGCTCCCATC R: CATCGGGAGGGCAGGCTC
Gly19Cys	Lund <i>et al</i> ⁸	3911 G/T	–	Exon 8 (2365)	F: GGAAGACTGGGATGAGGGCA R: GGCTCGCCAGGCTCACC
Ala897Thr	rs1800215	13 773 G/A	0.019	Exon 45 (9862)	F: CTCAGCTTCCTGGCCAA R: AGGCGGAAGTCCATTGGCATC

*SNP ID in the database dbSNP, www.ncbi.nlm.nih.gov/SNP/; †Bold-faced letters are the minor alleles; ‡Allele frequencies of the minor alleles; the T allele of SNP3 was not observed in our sample; §The numbers in parentheses are physical distances from the previous SNP in bp units; ¶The Sp1 polymorphism lies at position 1546 on the sequence AF017178 (GenBank accession number).

Table 3 Partial correlation coefficients between BMD at different skeletal sites

BMD	Lumbar spine	Total hip	Femoral neck	Trochanter	Intertrochanter	Ultradistal	Mid-distal	One-third	Total body
Lumbar spine		0.695	0.598	0.678	0.635	0.571	0.452	0.411	0.733
Total hip	0.684		0.831	0.888	0.962	0.640	0.517	0.453	0.745
Femoral neck	0.682	0.845		0.725	0.738	0.544	0.457	0.438	0.669
Trochanter	0.671	0.915	0.784		0.788	0.582	0.427	0.386	0.674
Intertrochanter	0.623	0.974	0.763	0.825		0.605	0.489	0.417	0.696
Ultradistal	0.542	0.590	0.557	0.562	0.552		0.790	0.627	0.673
Mid-distal	0.494	0.580	0.554	0.519	0.566	0.838		0.865	0.600
One-third	0.496	0.577	0.543	0.513	0.559	0.656	0.875		0.562
Total body	0.747	0.746	0.692	0.721	0.702	0.620	0.616	0.644	

Values above and below the diagonal indicate correlation coefficients for male and female subjects, respectively. All correlation coefficients are significantly larger than zero ($p < 0.001$).

families using the program Genehunter version 2.1 (<http://www.hgmp.mrc.ac.uk/Registered/Option/genehunter.html>).²⁷ The linkage disequilibrium between SNPs was calculated by Lewontin's measure.²⁸ Before the genetic analyses, the data were tested for measured potentially important covariates and adjusted for the significant ones (age, age², weight, and height) by a multiple stepwise regression procedure (carried out separately for each sex), using a significance level of 0.1 for both inclusion and retention in the model. All the data analyses were performed for male and female groups separately and implemented by using PROC REG, GLM, MANOVA, and PRINCOMP in SAS 8.0e. The experiment-wise significance level was set at 0.05.

RESULTS

Table 1 presents the basic characteristics of the male and female study subjects separately. The males had significant higher mean BMD at the nine skeletal sites than the females ($p < 0.001$), indicating gender effects on BMD variation. Table 2 gives minor allele frequencies of the four SNPs at the *COL1A1* gene. The T allele of the Gly19Cys was not observed in our sample. The minor allele frequencies of the PCOL2, Sp1, and Ala897Thr were 0.152, 0.187, and 0.019, respectively. To avoid reporting results based on only a few individuals (< 20) (also see Discussion), we only tested association of the common SNPs PCOL2 and Sp1 and their common haplotypes with BMD in the female and male groups. Table 3 provides partial correlation coefficients between BMD at different skeletal sites in both sexes. All the correlations were positive and highly significant ($p < 0.001$) and ranged from 0.417 to 0.974, indicating rich information on the relationship between different skeletal sites. The correlations in the females were generally larger than in the males ($p < 0.001$), indicating potential gender effects on BMD co-variation among skeletal sites.

No significant results were observed in the male group. Table 4 summarises results from univariate and multivariate association analyses for single SNPs in the female group. In

the univariate analyses, only a weak association of the PCOL2 with total body BMD ($p < 0.056$) was observed. This association was obviously not significant after Bonferroni correction. In the multivariate analysis, an enhanced association of the PCOL2 with composite BMD phenotypes was found with p values of 0.034 (Wilks' lambda) and 0.016 (Roy's largest root). Similar results were observed at the Sp1 with p values of 0.048 and 0.023, respectively. In the subsequent principal component analyses (PCA), the first three principal factor scores (FS) accounted for 74.4%, 10.1%, and 6.30% of the total BMD variation at the nine skeletal sites, respectively. p Values for univariate association analyses of the three factor scores FS1, FS2, and FS3 with the PCOL2 were 0.474, 0.029, and 0.074, respectively. Multivariate analysis of the

Table 4 p Values of association tests for each of the two SNPs with BMD in the female group

	PCOL2	Sp1
UANOVA of each BMD phenotype*		
Body BMD	0.056	0.805
MANOVA of the nine BMD phenotypes		
Wilks' lambda	0.034	0.048
Roy's largest root	0.016	0.023
UANOVA of each of the three FSs (PCA)		
FS1 (0.744)†	0.474	0.887
FS2 (0.101)	0.029	0.067
FS3 (0.063)	0.074	0.183
MANOVA of the three FSs (PCA)		
Wilks' lambda	0.024	0.152
Roy's largest root	0.007	0.112

*In the UANOVA analyses of each of the nine BMD phenotypes, only the body BMD showed a p value of 0.056 for the PCOL2; †The number in the parenthesis is the proportion that the FS (factor score) accounts for of the total BMD variation at the nine skeletal sites.

three factor scores produced stronger evidence for the association with the PCOL2 with p values of 0.024 (Wilks' lambda) and 0.007 (Roy's largest root). However, no increasing evidence for association was observed at the Sp1 in the PCA analyses.

Based on the interesting results for single SNPs found above, we further tested associations of the interaction of the PCOL2 and Sp1 and their haplotypes with BMD (table 5). The two SNPs were in significant linkage disequilibrium ($D' = 0.918$). The three common haplotypes *TG*, *GG* and *GT* had frequencies of 0.172, 0.616, and 0.210, respectively, while the other haplotype *TT* was rare with a frequency of 0.002 and thus was excluded from further analyses. The interaction of the PCOL2 and Sp1 showed highly significant evidence for the association of BMD phenotypes ($p = 0.003$ for Wilk's lambda and $p = 0.001$ for Roy's largest root). Significant evidence was only found at the haplotype *GG* ($p = 0.026$ for Wilk's lambda and $p = 0.006$ for Roy's largest root) and carriers of the *GG* haplotype had, on average, 2.7% higher BMD than non-carriers.

DISCUSSION

In the present study, we analysed the association of the common SNPs at the *COL1A1* gene and their haplotypes with BMD phenotypes in elderly Caucasians. We found a strong association between the PCOL2 and BMD phenotypes and a suggestive association between the Sp1 and BMD phenotypes in the elderly females. Interestingly, the interaction of the PCOL2 and Sp1 was shown to be most significantly associated with BMD variation. Of their four haplotypes, strong evidence was also found for the haplotype *GG* in relation to BMD variation.

Association of the *COL1A1* gene with BMD and its putative molecular mechanisms

To date, a number of studies have been performed to test whether allelic variants of the *COL1A1* gene can be associated with variations in osteoporosis phenotypes. The tested PCOL2 (-1997 G/T), named by Garcia-Giralt *et al.*,¹⁹ was recently found within the *COL1A1* promoter region known to harbour cis elements important for in vivo expression.¹⁹ This polymorphism site may bind primary osteoblast nuclear proteins and was reported to be significantly associated with BMD values at the lumbar spine and femoral neck in postmenopausal women of Spanish origin.¹⁹ However, no further study on this SNP has been documented. Our results confirmed this positive association in a cohort of elderly Caucasian women. Similar analyses did not reveal such an association in elderly Caucasian men.

The tested Sp1 was one of the most frequently studied polymorphisms affecting a binding site for the transcription factor Sp1 in the *COL1A1* gene. The polymorphism Sp1 site

lies within the first intron of the *COL1A1* gene and was first reported to be associated with BMD and osteoporosis fractures by Grant *et al.*² Our results provide suggestive evidence for an association of the Sp1 polymorphism and BMD phenotypes in elderly Caucasian women. Several other studies have also confirmed the positive association with bone loss in elderly populations.^{5 7 10 12} Recently, a meta-analysis of 26 studies confirmed the association for the *T* allele of the Sp1 polymorphism with a modest reduction in BMD and a significant risk of osteoporotic fracture.⁹ However, conflicting results were also reported in younger populations, such as Norwegian young adults,⁶ American premenopausal women,⁸ Irish young men and women,¹¹ and French premenopausal women.¹³ In our analyses, we did not find any association of the Sp1 polymorphism with BMD phenotypes in elderly men. This is consistent with most previous studies,^{5 7 10 12} suggesting that the *COL1A1* gene may exert a greater influence on BMD variation in females than in males or there may be gender heterogeneity of the *COL1A1* gene on BMD.

The most remarkable finding here is that the interaction of the PCOL2 and Sp1 may play an important role in contributing to BMD variation besides their respective effects. In our female sample, after adjusting for age, age², height, and weight, subjects with the PCOL2 *G* allele had an average of 1.5% higher BMD values than those without this allele. Subjects carrying the Sp1 *G* allele had 0.5% higher mean BMD values than non-carriers. However, haplotype *GG* carriers had, on average, 2.7% higher BMD values than non-carriers, indicating a larger haplotype joint effect than their accumulated individual effects on BMD variation. Interestingly, the PCOL2 was found to interact with another SNP in the promoter of *COL1A1*, namely PCOL1 (-1663 indelT) that was in strong linkage disequilibrium with the Sp1.¹⁹ Bornstein *et al.*²⁰ proposed that normal regulation of *COL1A1* gene transcription may result from the interplay of positive and negative elements present in the promoter region and within the first intron. Recently, Mann *et al.*⁴ found that the *T* allele (that is, "s" allele) of the Sp1 polymorphism has higher binding affinity for Sp1 protein compared with the *G* allele (that is, "S" allele). Higher affinity for Sp1 protein at the *T* allele increases the relative abundance of collagen $\alpha 1(I)$ to $\alpha 2(I)$ protein chains in "TG" heterozygotes that is accompanied by an increase in the relative abundance of *COL1A1* to *COL1A2* mRNAs. The abnormal relative level of *COL1A1* to *COL1A2* mRNAs may reduce bone quality and quantity.⁴ In addition, gel retardation assays demonstrated that the *G* allele of the PCOL2 polymorphism has a higher binding capacity of single-stranded binding proteins.¹⁹ The single-stranded binding proteins may repress transcription either by preventing access of dsDNA binding factors (such as Sp1 protein mentioned above) or by stabilising a secondary structure, which would prevent their binding.¹⁹ It seems that the allelic variants at the PCOL2 and Sp1 binding sites may interact in transcription regulation of the *COL1A1* gene. This may partially explain the larger haplotype difference between the haplotype *GG* carriers and non-carriers and the most significant association of the interaction of the PCOL2 and Sp1 polymorphisms with BMD phenotypes in our study.

Statistical issues involved in analyses and their implications

The results from our comparative analyses also have important implications for association studies in bone fields. The multivariate analyses revealed strong and/or suggestive evidence for association of the *COL1A1* gene with BMD phenotypes, while the univariate analyses largely failed to detect such an association (table 4). BMD variation at various skeletal sites may share common genetic sources.²²⁻²⁵ In the

Table 5 p Values of association tests for the interaction of the PCOL2 and Sp1 and their haplotypes with BMD in the female group*

	SNP interaction	Haplotypes†		
	PCOL2×Sp1	TG (0.172)‡	GG (0.616)	GT (0.210)
Wilks' lambda	0.003	0.203	0.026	0.486
Roy's largest root	0.001	0.203	0.006	0.486

*MANOVA of the nine BMD phenotypes was performed for the interaction of the PCOL2 and Sp1 and their haplotypes; †The rare haplotype *TT* with a frequency of 0.003 was not tested in the analyses (see text); ‡The number in the parenthesis is the haplotype frequency.

present sample, we observed highly significant correlations between BMD at various skeletal sites (table 3). From a statistical point of view, multivariate analysis has several advantages over its simpler univariate counterpart.³⁰ First, multivariate analysis exploits important information regarding the relationship between dependent variables (such as different BMD measurements here) and thus may reveal differences not shown in the multi-fold univariate analyses. Second, multivariate analysis obviates multiple testing problems that arise in univariate analyses and thus may increase statistical power. From a biological point of view, multivariate analyses of BMD phenotypes jointly may decrease the effect of developmental randomness during ontogenesis of various skeletal sites. Therefore, multivariate association analysis may be more powerful than multi-fold univariate association analyses as shown in our results. It should be noted, however, that univariate analysis is warranted in some situations, for example, when there is genetic heterogeneity among surrogate phenotypes of complex diseases.³¹

The SNPs Gly19Cys in exon 8 and Ala897Thr in exon 45 are very rare with frequencies of <2% in our sample. The two rare variants may also play a role in influencing BMD variation. However, identification of such rare variants using association studies will pose a daunting challenge. We simulated a functional mutation allele with a minor frequency of 2% and responsible for 1% phenotypic variation under additive inheritance in the general population. Simulations were performed in 10 000 replicates using a significance level of 0.05. To achieve 80% power for association analysis, the sample size required for finding such a rare variant was approximately 4200 unrelated subjects, while in the same situation only about 160 subjects would be required if the frequency of the functional allele was increased to 15%. Thus, larger sample sizes are required for future investigation of such rare variants.

In addition, our sample was from 405 nuclear families with a total of 1873 subjects. We also performed transmission disequilibrium tests (TDT) in these nuclear families and did not find any significant/suggestive association between the common SNPs and BMD phenotypes (Liu *et al*, unpublished). Since the TDT analyses only utilize phenotype information of informative offspring, it may lose considerable statistical power compared with association analyses. However, association studies may yield spurious results due to population substructure. Several studies showed that population substructure may not be a problem for association studies in US Caucasian populations,³² including our recent data for our study population.³³ The study subjects were recruited from a population of relatively homogenous ethnic background and population stratification was not observed.³³ Therefore, the results obtained in the present study should be robust and reliable.

CONCLUSIONS

Our data suggest that the common genetic variants at the PCOL2 and Sp1 sites of the *COL1A1* gene, and importantly, their interactive effects, may contribute to BMD variation in elderly Caucasian females. Further studies are necessary to delineate the mechanisms underlying the effects of these common genetic variants on BMD variation and to test their clinical relevance for general populations. In addition, our study highlighted the importance of multivariate analyses when multiple correlated phenotypes are under study.

Authors' affiliations

P-Y Liu, Y Lu, J-R Long, F-H Xu, H Shen, R R Recker, H-W Deng, Osteoporosis Research Center, Creighton University, Omaha, NE 68131, USA

F-H Xu, H Shen, H-W Deng, Department of Biomedical Sciences, Creighton University, Omaha, NE 68131, USA

H-W Deng, Laboratory of Molecular and Statistical Genetics, College of Life Sciences, Hunan Normal University, Changsha, Hunan 410081, China

The study was partially supported by grants from the Health Future Foundation, NIH and the State of Nebraska. The study was also benefited by grants from CNSF, the Huo Ying Dong Education Foundation, and the Ministry of Education of China.

Conflict of interest: none declared.

REFERENCES

- 1 **Consensus Development Conference.** Bone mass and fracture risk. *Am J Med* 1993;**95**:1S-78S.
- 2 **Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH.** Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. *Nat Genet* 1996;**14**:203-5.
- 3 **Byers PH.** Brittle bones—fragile molecules: disorders of collagen gene structure and expression. *Trends Genet* 1990;**6**:293-300.
- 4 **Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, Aspden RM, Ralston SH.** A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. *J Clin Invest* 2001;**107**:899-907.
- 5 **Braga V, Mottes M, Mirandola S, Lisi V, Malerba G, Sartori L, Bianchi G, Gatti D, Rossini M, Bianchini D, Adami S.** Association of CTR and COL1A1 alleles with BMD values in peri- and postmenopausal women. *Calcif Tissue Int* 2000;**67**:361-6.
- 6 **Berg JP, Lehmann EH, Stakkestad JA, Haug E, Halse J.** The Sp1 binding site polymorphism in the collagen type I alpha 1 (COL1A1) gene is not associated with bone mineral density in healthy children, adolescents, and young adults. *Eur J Endocrinol* 2000;**143**:261-5.
- 7 **Harris SS, Patel MS, Cole DE, Dawson-Hughes B.** Associations of the collagen type I alpha 1 Sp1 polymorphism with five-year rates of bone loss in older adults. *Calcif Tissue Int* 2000;**66**:268-71.
- 8 **Hustmyer FG, Liu G, Johnston CC, Christian J, Peacock M.** Polymorphism at an Sp1 binding site of COL1A1 and bone mineral density in premenopausal female twins and elderly fracture patients. *Osteoporos Int* 1999;**9**:346-50.
- 9 **Mann V, Ralston SH.** Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. *Bone* 2003;**32**:711-7.
- 10 **MacDonald HM, McGuigan FA, New SA, Campbell MK, Golden MH, Ralston SH, Reid DM.** COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss. *J Bone Miner Res* 2001;**16**:1634-41.
- 11 **McGuigan FE, Murray L, Gallagher A, Davey-Smith G, Neville CE, Van't Hof R, Boreham C, Ralston SH.** Genetic and environmental determinants of peak bone mass in young men and women. *J Bone Miner Res* 2002;**17**:1273-9.
- 12 **Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, Grant SF, Hofman A, van Leeuwen JP, Pols HA, Ralston SH.** Relation of alleles of the collagen type I alpha 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. *N Engl J Med* 1998;**338**:1016-21.
- 13 **Garnero P, Borel O, Grant SF, Ralston SH, Delmas PD.** Collagen alpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. *J Bone Miner Res* 1998;**13**:813-7.
- 14 **Liu YZ, Liu YJ, Recker RR, Deng HW.** Molecular studies of identification of genes for osteoporosis: the 2002 update. *J Endocrinol* 2003;**177**:147-96.
- 15 **Deng HW, Shen H, Xu FH, Deng HY, Conway T, Zhang HT, Recker RR.** Tests of linkage and/or association of genes for vitamin D receptor, osteocalcin, and parathyroid hormone with bone mineral density. *J Bone Miner Res* 2002;**17**:678-86.
- 16 **Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C.** Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. *J Bone Miner Res* 1994;**9**:1503-14.
- 17 **Recker R, Lappe J, Davies K, Heaney R.** Characterization of perimenopausal bone loss: a prospective study. *J Bone Miner Res* 2000;**15**:1965-73.
- 18 **Lund AM, Jensen BL, Nielsen LA, Skovby F.** Dental manifestations of osteogenesis imperfecta and abnormalities of collagen I metabolism. *J Craniofac Genet Dev Biol* 1998;**18**:30-7.
- 19 **Garcia-Giralt N, Nogues X, Enjuanes A, Puig J, Mellibovsky L, Bay-Jensen A, Carreras R, Balcells S, Diez-Perez A, Grinberg D.** Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. *J Bone Miner Res* 2002;**17**:384-93.
- 20 **O'Connell JR, Weeks DE.** PedCheck: a program for identification of genotype incompatibilities in linkage analysis. *Am J Hum Genet* 1998;**63**:259-66.
- 21 **Merlter CA, Vannatta RA.** *Advanced and multivariate statistical methods: practical application and interpretation.* Los Angeles: Pyczak, 2001.
- 22 **Deng HW, Livshits G, Yakovenko K, Xu FH, Conway T, Davies KM, Deng H, Recker RR.** Evidence for a major gene for bone mineral density/content in human pedigrees identified via probands with extreme bone mineral density. *Ann Hum Genet* 2002;**66**:61-74.
- 23 **Deng HW, Stegman MR, Davies KM, Conway T, Recker RR.** Genetic determination of variation and covariation of peak bone mass at the hip and spine. *J Clin Densitom* 1999;**2**:251-63.
- 24 **Livshits G, Karasik D, Pavlovsky O, Kobylansky E.** Segregation analysis reveals a major gene effect in compact and cancellous bone mineral density in 2 populations. *Hum Biol* 1999;**71**:155-72.

- 25 **Karasik D**, Hannan MT, Kiel DP, Bouxsein ML, Cupples LA. Is a factor score combining dual X-ray absorptiometry and ultrasound a better phenotype for genetic studies? *J Bone Miner Res* 2002;**17**(suppl 1):S236.
- 26 **Lauter J**. Exact t and F tests for analysing studies with multiple endpoints. *Biometrics* 1996;**52**:964–70.
- 27 **Kruglyak L**, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. *Am J Hum Genet* 1996;**58**:1347–63.
- 28 **Lewontin RC**. The interaction of selection and linkage. I. General considerations; heterotic models. *Genetics* 1964;**49**:49–67.
- 29 **Bornstein P**, McKay J, Morishima JK, Devarayalu S, Gelinis RE. Regulatory elements in the first intron contribute to transcriptional control of the human alpha 1(I) collagen gene. *Proc Natl Acad Sci U S A* 1987;**84**:8869–73.
- 30 **Tabachnic BG**, Fidell LS. *Using multivariate statistics*. New York: Harper Collins, 1996.
- 31 **Huang QY**, Xu FH, Shen H, Deng HY, Conway T, Liu YJ, Liu YZ, Li JL, Li MX, Davies KM, Recker RR, Deng HW. Genome scan for QTLs underlying bone size variation at ten refined skeletal sites: genetic heterogeneity and the significance of phenotype refinement. *Physiol Genomics* 2004, in press. Epub ahead of print: PubMed ID 15039485.
- 32 **Ardlie KG**, Lunetta KL, Seielstad M. Testing for population subdivision and association in four case-control studies. *Am J Hum Genet* 2002;**71**:304–11.
- 33 **Long JR**, Liu PY, Liu YJ, Lu Y, Xiong DH, Elze I, Recker RR, Deng HW. APOE and TGF-beta1 genes are associated with obesity phenotypes. *J Med Genet* 2003;**40**:918–24.